ZYLiQ Unveils Version 4.0 for Enhanced Medical Writing Automation
Introduction
In a significant leap for the medical writing sector, ZYLiQ has officially announced the launch of Version 4.0 of their cutting-edge software, renowned for its application of Artificial Intelligence (AI) and Machine Learning (ML) in regulatory medical writing. With this latest version, ZYLiQ sets a new standard for automation and efficiency, especially in the realm of clinical study reporting (CSR).
A Leader in Regulatory Writing
ZYLiQ has established its position as a pioneer in the field of generative AI tailored for regulatory documentation, claiming to boost CSR production by a remarkable 75%. Customers have been consistently renewing their contracts, which underscores the platform's innovative approach to solving the complexities within regulatory writing.
New Features Introduced
The release of Version 4.0 comes packed with a suite of enhancements designed to streamline the automation process for CSR:
1.
Automatic Source-Type Prediction: Users can now benefit from automatic predictions of source types for any sections they add.
2.
Optimized Synopsis Content Creation: Enhancements in the synthesis of summary content have been implemented.
3.
GenAI-Powered Tense Conversion and Lean Writing: This feature facilitates tension adjustments in narratives, thus enabling concise writing and in-text summary generation.
4.
AI-Assisted Safety and Efficacy Conclusions: The drafting process of these vital sections has become more accessible and efficient.
Introduction of New Regulatory Modules
In a strategic move to extend its capabilities beyond CSR, ZYLiQ Version 4.0 incorporates several new modules aimed at generating various regulatory documents using generative AI. Let's delve into these innovative additions:
- - Safety Narratives: Designed to rapidly generate safety narratives, this module automatically extracts relevant data from listings, SDTM/ADaM datasets, and patient profiles, enabling users to report a striking 90% reduction in completion time.
- - Informed Consent Form (ICF) Generation: By ingesting the protocol and investigator brochure materials, this module aids users in crafting ICFs with the added benefit of utilizing specific sponsor templates.
- - Plain Language Summaries (PLS): This module produces plain language summaries directly from CSR inputs, making technical information more accessible to non-experts.
- - Protocol Plain Language Summary (PLPS): Similar to PLS, but tailored for protocol documentation, ensuring comprehensibility for a broader audience.
- - Redaction and Anonymization: Essential for protecting sensitive information, this feature allows users to mask or anonymize confidential data within documents effortlessly.
Free Pilot Program
In an effort to prove the effectiveness of their advanced solutions, ZYLiQ provides prospective clients with a free two-week pilot. This initiative enables companies to directly compare traditional documentation processes with the rapid automation capabilities offered by ZYLiQ, showcasing the value and time-saving benefits of their platform.
Vision for the Future
"Our concentrated effort on the automation of regulatory documents—rather than diversifying across multiple document types—has empowered us to create a highly efficient solution," states Farha Feroze, ZYLiQ’s Inventor and Director of Product Management. With the rollout of Version 4.0, ZYLiQ is poised to replicate its successes in CSR across other regulatory documents. The commitment to adopting advanced technologies and addressing client needs sets a strong precedent for future innovations.
About ZYLiQ
With a foundation built on over thirty years of expertise from the Clinical Research Organization Symbiance, ZYLiQ harmonizes extensive domain knowledge in life sciences with proven technological prowess. The result is a sophisticated platform that directly addresses the pain points faced by customers in the regulatory writing landscape.
Get in Touch
For more information or to book a demo, visit
ZYLiQ's Website or contact them directly at +1 949-878-2121.